SCHEMBL214811

SCHEMBL214811

Nc1nn(C2CC2)c2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.37
RPS6KB1 P23443 1/20 0.36
ROCK1 Q13464 1/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.35
ELANE P08246 1/20 0.35
TTK P33981 1/20 0.35
SCD O00767 1/20 0.34
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
SSTR4 P31391 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 3/20 0.33
MAPK1 P28482 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30780929 1.00 DHFR (0.37) DHFRRPS6KB1ROCK1HPGDKDM4E
SCHEMBL29195498 0.86 TEAD1 (0.42) HPGDELANESCDRET
SCHEMBL30856671 0.86 TEAD1 (0.42) HPGDELANESCDRET
SCHEMBL23937822 0.78 ESR1 (0.36) HPGDKDM4ESCDPDE4APDE4B
SCHEMBL28871268 0.76 KDM4E (0.31) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL20764905 0.75 GAA (0.42) KDM4EALDH1A1HSD17B10MAPK1MEN1
SCHEMBL24117847 0.74 PTGDR2 (0.40) SCDPDE4APDE4BPDE4CPDE4D
SCHEMBL24117840 0.74 ALDH1A1 (0.36) KDM4ESCDPDE4APDE4BPDE4C
SCHEMBL31429395 0.73 CYP3A4 (0.44) KDM4EELANESSTR4ALDH1A1HSD17B10
SCHEMBL23559557 0.72 HCAR3 (0.51) KDM4EHSD17B10CNR1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030651-A1 GPX4 INHIBITORS AND USE THEREOF SONATA THERAPEUTICS, INC. (US) 2024-02-08 WO disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK DHFR 640/4885RPS6KB1 91/4885ROCK1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.